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Background: The efficacy, potency, and selectivity of the compound 2-Chloro-5-hydroxyphenylglycine (CHPG), a
nominally selective agonist for metabotropic glutamate receptor 5 (mGluR5), were examined with select mGluRs by
examining their ability to induce modulation of the native voltage dependent ion channels in isolated sympathetic
neurons from the rat superior cervical ganglion (SCG). SCG neurons offer a null mGluR-background in which specific
mGluR subtypes can be made to express via intranuclear cDNA injection.
Results: Consistent with previous reports, CHPG strongly activated mGluR5b expressed in SCG neurons with an
apparent EC50 around 60 μM. Surprisingly, CHPG also activated two mGluR1 splice variants with a similar potency as
at mGluR5 when calcium current inhibition was used as an assay for receptor function. No effect of 1 mM CHPG
was seen in cells expressing mGluR2 or mGluR4, suggesting that CHPG only activates group I mGluRs (mGluR1 and
5). CHPG was also able to induce modulation of M-type potassium current through mGluR1, but not as consistently
as glutamate. Since this channel is modulated through a Gq-dependent pathway, these data indicate that CHPG
may exhibit some biased agonist properties on mGluR1. Closer examination of the voltage-independent, Gq-
mediated component of mGluR-induced calcium current modulation data confirmed that some biased agonism
was evident, but the effect was weak and inconsistent.
Conclusions: These data contrast with the established literature which suggests that CHPG is a selective mGluR5
agonist. Instead, CHPG appears to act equally well as an agonist at mGluR1. While some weak biased agonism was
observed with CHPG acting on mGluR1, but not mGluR5, favoring Gi/o signaling over Gq/11, this effect does not
appear sufficient to fully explain the discrepancies in the literature.Background
Metabotropic glutamate receptors (mGluRs) are important
mediators of learning and excitability [1,2], sensory signal
transduction [3], and central information processing that
play a critical role in many physiological and pathological
processes [4]. The group I mGluRs, which includes mGluR1
and 5, exhibit widespread expression in the central nervous
system where they are generally expressed postsynaptically
in addition to their dendro-somatic localization, where they
can initiate some forms of plasticity and regulate neuronal
excitability, respectively [1,2]. mGluR1 and 5 are similar in
sequence, G protein coupling and in their responses toCorrespondence: paul_kammermeier@urmc.rochester.edu
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reproduction in any medium, provided the ormany pharmacological compounds. While their expression
profiles in the brain are distinct, mGluR1 and 5 serve analo-
gous roles in different regions. For example, hippocampal
mGluR5 localized near the postsynaptic density can initiate
a form of long term depression (mGluR-LTD) [1,5,6]. Like-
wise, postsynaptic mGluR1 in the cerebellum can also pro-
duce mGluR-LTD [1,2,7]. In both cases, initiation of
plasticity requires coupling to Gq/11 proteins and post-
synaptic localization, although the mechanistic details of
each phenomena are distinct. Further, both mGluR1 and 5
can couple to modulation of voltage gated calcium and
other ion channels in several neuronal cell types [8-11],
leading to changes in cell excitability.
Our understanding of the role of these receptors
derives in large part from the pharmacological tools used
to manipulate their function. In recent years, many highlyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mGluRs at allosteric sites, separate from the endogenous
glutamate ligand binding site. Fewer highly selective
orthosteric compounds are available. One exception is the
compound 2-Chloro-5-hydroxyphenylglycine (CHPG), an
orthosteric ligand that has been used extensively as a
selective mGluR5 agonist [12]. At least one report indi-
cates that CHPG is selective for mGluR5 over even the
closely related mGluR1, making it the only known orthos-
teric agonist with such selectivity [12]. However, the select-
ivity of CHPG for mGluR5 over mGluR1 has not been
subsequently tested, to my knowledge.
Here, selectivity of CHPG was examined by testing its
ability to activate specific mGluRs expressed by intranuc-
lear cDNA injection in sympathetic neurons from the rat
superior cervical ganglion (SCG), a primary neuronal cell
with a null mGluR background [13]. Modulation of the
native voltage-dependent calcium currents in SCG neu-
rons was used as an assay for heterologously expressed
mGluRs. The ability of a range of concentrations of
CHPG to activate mGluR5, mGluR2, mGluR4, and two
splice variants of mGluR1 (a and b) was tested. Consist-
ent with previous reports in the literature, we found that
CHPG functioned as a full agonist at mGluR5 and failed
to activate mGluR2, or mGluR4. Surprisingly however,
CHPG also functioned as a full agonist at both mGluR1a
and mGluR1b with similar potency as mGluR5.Methods
Cell isolation, DNA injection and Plasmids
A description of cell isolation and cDNA injection is
found elsewhere [14]. Animal protocols were approved by
the university committee on animal resources (UCAR).
Briefly, SCGs were removed from adult male Wistar rats
(175–225 g) after CO2 euthanasia and decapitation, then
incubated in Earle’s balanced salt solution (InVitrogen, Life
Technologies Carlsbad, CA) containing 0.6 mg/ml trypsin
(Worthington Biochemicals, Freehold, NJ) & 0.8 mg/ml
collagenase D (Boehringer Mannheim Biochemicals, In-
dianapolis, IN) for 60 min at 35°C. Cells were transferred
to minimum essential medium (InVitrogen/Gibco), pla-
ted on poly-L-lysine (Sigma Chemical Co., St. Louis,
MO) coated culture dishes and incubated at 37°C for
2–4 hours before cDNA injection. Injected cells were
incubated overnight at 37°C (95% air and 5% CO2; 100%
humidity) and patch clamp experiments were per-
formed the next day.
Injection of cDNA was performed with an Eppendorf
5247 microinjector and InjectMan NI 2 micromanipula-
tor (Madison, WI) 3–5 hours following cell isolation. In-
jection electrodes were made with a Sutter P-97 horizontal
electrode puller (Novato, CA) from thin-walled, borosili-
cate glass (World Precision Instruments, Sarasota, FL).Plasmids were stored at −20°C as a 0.4 - 1 μg/μl stock so-
lution in TE buffer (10 mM TRIS, 1 mM EDTA, pH 8).
All mGluR constructs were injected at 100–130 ng μl-1
(pCDNA3.1+; InVitrogen). The mGluR4 clone was pro-
vided by D. Hampson (University of Toronto, Toronto,
Onatrio, Canada). All neurons were co-injected with
“enhanced” green fluorescent protein cDNA (0.02 μg/μl;
pEGFPN1; BD Biosciences-Clontech, Palo Alto, CA) for
identification of successfully injected cells.
All constructs were sequence confirmed. PCR products
were purified with Qiagen (Valencia, CA) silica membrane
spin columns prior to restriction digestion and ligation.
Midipreps were prepared using Qiagen anion exchange
columns, and amplified in either Top10 or DH5α E. coli.
(InVitrogen).Electrophysiology and data analysis
Pipettes for patch-clamp experiments were made with a
Sutter P-97 horizontal puller from 8250 glass (Garner Glass,
Claremont, CA) and had resistances of 1–3 MΩ. Series
resistances were 2.3±0.2 MΩ (n=31) prior to electronic
compensation of 80%. Whole-cell patch-clamp recordings
were made with an EPC-7 patch clamp amplifier (Heka
Elektronik, Germany). Voltage protocol generation and data
acquisition were performed using custom software (courtesy
Stephen R. Ikeda, NIAAA, Rockville, MD) on a Macintosh
G4 computer (Apple Computer, Cupertino, CA) with an
InstruTech (Port Washington, NY; now Heka Elektronik)
ITC-16 data acquisition board. Currents were low-pass
filtered at 3 kHz using the 4-pole Bessel filter in the patch
clamp amplifiers, digitized at 2–5 kHz and stored on the
computer for later analysis. Experiments were performed at
21–24°C (room temperature). Patch-clamp data analysis
was performed using the Igor Pro software package (Wave-
metrics, Lake Oswego, OR).
The external (bath) recording solution contained (in
mM): 155 tris hydroxymethyl aminomethane, 20 4-(2-
Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
10 glucose, 10 CaCl2, and 0.0003 tetrodotoxin (TTX),
pH 7.4. The internal (pipette) solution contained: 120 N-
methyl-D-glucamine (NMG) methanesulfonate, 20 TEA,
11 EGTA, 10 HEPES, 10 sucrose, 1 CaCl2, 4 MgATP, 0.3
Na2GTP, and 14 tris creatine phosphate, pH 7.2. L-
Glutamate (Sigma) was used as the agonist for mGluRs.
CHPG was obtained from two sources: Tocris Bioscience
(Ellisville, MO) and Ascent Scientific (Avonmouth, Bris-
tol, UK). All drugs and control solutions were applied to
cells using a custom, gravity-driven perfusion system
positioned ~100 μm from the cell, allowing rapid solu-
tion exchange (≤ 250 ms). The degree of calcium current
inhibition was calculated as the maximum current inhib-
ition in the presence of drug compared to the last
current measurement prior to drug application.
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CHPG activates mGluR5
To confirm the utility of CHPG as an agonist of mGluR5,
and to estimate its efficacy and potency in our system, iso-
lated SCG neurons were intranuclearly injected with
cDNA encoding rat mGluR5b, and the amplitude of
calcium currents was monitored using the whole-cell
configuration of the patch-clamp technique upon applica-
tion of multiple concentrations of CHPG and L-glutamate
(Glu) (Figure 1). Currents were monitored during a
25 msec test pulse to +10 mV from a holding potential of
−80 mV (Figure 1A, inset), near the peak of the current–
voltage (I-V) curve. CHPG application produced a dose-
dependent, reversible inhibition of the calcium current, as
illustrated in the representative current amplitude time
course shown in Figure 1A. At saturating concentrations
the CHPG effect was similar to the inhibition produced
with Glu (Figure 1A, B). Figure 1B shows the average
(±SEM) current inhibition by CHPG at each concentra-
tion. A fit of these data to the Hill equation {% inhibition=
EMAX/(1+ [[CHPG]half/[CHPG]
rate)} is also shown, yield-
ing an EC50 value of 57 μM. These data are consistent with
those reported in the literature and confirm that CHPG
acts as an agonist at mGluR5 with an EC50 value in the
mid to high μM range.
Effect of CHPG on other mGluRs
The specificity of CHPG was tested by examining its ef-
fect on calcium currents in neurons expressing either
mGluR2, mGluR4, mGluR1a or mGluR1b. SCG neurons
expressing either mGluR2 or mGluR4, group II and III
mGluRs, respectively, which couple exclusively to Gi/o
proteins and with greater sequence divergence from
mGluR5 (compared to mGluR1), were exposed to












Figure 1 CHPG induces strong calcium current modulation in SCG ne
(inset) illustrating the magnitude of calcium currents in a representative SCG
indicated. Voltage protocol consisted of a 25 msec step to +10 mV from a
10 msec. B, Average (±SEM) calcium current inhibition at a range of CHPG
11, and 7, respectively).expressing cells examined showed strong Glu-dependent
calcium current inhibition (average of 44 ± 7%, n = 4),
confirming expression of the receptor (Figure 2). How-
ever, none of these cells exhibited detectable current
modulation upon application of 1 mM CHPG (0 ± 2%,
n = 4). Likewise, SCG neurons expressing mGluR4 were
inhibited 20 ± 4% (n = 4) by 100 μM Glu, but unaffected
by 1 mM CHPG (2 ± 2%, n = 4). These data confirm that
CHPG is not an agonist at mGluR2 or 4.
The effects of CHPG were further tested on SCG neu-
rons expressing either mGluR1a or a similar splice vari-
ant, mGluR1b. Surprisingly, strong CHPG-mediated
calcium current modulation was observed in neurons
expressing both mGluR1a and mGluR1b (Figure 3A, B).
Figure 3A illustrates the time course of inhibition in one
SCG neuron expressing mGluR1a upon application of
100 μM Glu and several concentrations of CHPG (as
indicated). The inset in Figure 3A shows sample currents
from the same cell illustrating a control (uninhibited)
current, and current inhibited by 3 mM CHPG.
Figure 3B illustrates the average (± SEM) CHPG effect at
four different concentrations from 12 SCG neurons
expressing mGluR1a and 7 cells expressing mGluR1b.
The data were fit to the Hill equation (as in Figure 1B),
which indicated an EC50 value of 80 μM for mGluR1a
and 39 μM for mGluR1b, both values similar to that
observed with mGluR5 (Figure 1). These data suggest
that while CHPG shows strong selectivity for group I
mGluRs over mGluR2 and 4, it appears to activate
mGluR1 with similar potency as its known target,
mGluR5.
Efficacy of CHPG on mGluR5 and mGluR1
To compare the efficacy of CHPG on mGluR5 with the
mGluR1 variants, the responses (percentage inhibition ofurons expressing mGluR5. A, Time course and sample current traces
neuron and inhibition by various concentrations of CHPG and Glu, as
holding potential of −80 mV. Scale bars in inset represent 1 nA and
concentrations (for [CHPG] ranging from 10 μM to 3 mM, n = 6, 3, 8, 4,
Figure 4 Efficacy and potency of CHPG were similar for SCG
calcium current modulation in cells expressing mGluR5b,
mGluR1a, and mGluR1b. Calcium current inhibition by each
concentration of CHPG was normalized to that by 100 μM Glu in
each cell, and plotted here. Neither efficacy nor potency of CHPG’s
effects on mGluR1a, 1b or 5b were statistically distinguishable.
Figure 2 CHPG does not activate group II or III mGluRs. Average
(± SEM) calcium current inhibition by 100 μM Glu and 1 mM CHPG
in SCG neurons expressing mGluR2 (left) or mGluR4 (right). Both Glu
and CHPG were applied to each cell. Number of cells in each group
shown in parentheses.
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were normalized to the response to 100 μM Glu in the
same cell. These normalized CHPG responses were then











Figure 3 CHPG induces strong calcium current modulation in SCG neu
current traces (inset) illustrating the magnitude of calcium currents in a rep
concentrations of CHPG and by 100 μM Glu, as indicated. Cells were held a
bars represent 0.5 nA and 10 msec. B, Dose response curves for CHPG in ce
indicated. For mGluR1a, n = 12 at all concentrations. For mGluR1b (30–3000a saturating concentration of the natural ligand (and full
agonist) of mGluRs, a saturating response of 1 in this
plot is indicative of full agonism. Each of these data sets
were fit to the Hill equation and responses to mGluR5,
mGluR1a, and mGluR1b reached a maximal response of
1.05 ± 0.09 (n = 8), 0.99 ± 0.02 (n = 12), and 1.23 ± 0.04rons expressing mGluR1a and 1b. A, Time course and sample
resentative mGluR1a expressing SCG neuron and inhibition by various
t −80 mV and current was elicited by a 25 msec step to +10 mV. Scale
lls expressing mGluR1a (open circles) or mGluR1b (open diamonds, as
μM), n = 5, 6, 7 and 7, respectively.
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as a full agonist at mGluR5, mGluR1a and mGluR1b.
Note that the number of cells in the mGluR5 data set
was somewhat smaller than in Figure 1, because only
cells to which 100 μM Glu was applied could be analyzed
in this way.
To further verify the action of CHPG on these recep-
tors, calcium current inhibitory responses of SCG neu-
rons to 1 mM CHPG were examined in cells expressing
either mGluR5b or 1a in the absence and presence of the
selective mGluR5 inhibitor MPEP and the selective
mGluR1 inhibitor LY367385. The results of those experi-
ments are shown in Figure 5. In six mGluR5b expressing
cells, 1 mM CHPG produced an average inhibition of the
calcium currents of 37 ± 4% when applied alone. In the
presence of 1 μM MPEP, CHPG produced only 5 ± 2%
inhibition, as expected. When CHPG was applied in the
presence of 50 μM LY367385, CHPG inhibited the
current by 37 ± 3%, an effect indistinguishable from that
when CHPG was applied alone. In five mGluR1a expres-
sing cells, CHPG produced a 45± 7% inhibition when ap-
plied alone, and 45 ± 8% and 9 ± 3% in the presence of
MPEP and LY367385, respectively. These results confirm
that CHPG is indeed acting through the heterologously
expressed receptor in both mGluR5 and mGluR1 expres-
sing SCG neurons, and are thus inconsistent with theFigure 5 Effect of selective inhibitors on CHPG effects in
mGluR5b and 1a expressing cells. Average (± SEM) calcium
current inhibition produced by application of 1 mM CHPG alone
(black) or in the presence of 1 μM MPEP (gray) or 50 μM LY367385
(white) in SCG neurons expressing the indicated receptor. Number of
cells in each group shown in parentheses.plausible explanation that native mGluR5 might be upre-
gulated in SCG neurons when mGluR1 is expressed
heterologously.
CHPG shows weak biased agonist properties when acting
on mGluR1 but not mGluR5
A potential explanation for the discrepancy between the
data presented here, showing CHPG acting as an mGluR1
agonist, and that in the established literature suggesting
that CHPG is selective for mGluR5 over mGluR1, may be
that CHPG acts as a biased agonist on mGluR1. This is
possible because although the group I mGluRs (mGluR1/
5) are generally considered to be Gq-coupled receptors,
they are in fact dual coupled, activating Gq/11 and Gi/o in
many neurons [8-11], or Gq/11 and Gs in some heterol-
ogous expression systems [15-17]. As such it is possible
that mGluR1 agonism was missed in earlier studies, since
many of these used fluorescent calcium indicators to de-
tect mGluR-induced rises in intracellular calcium as an
assay for mGluR5 and mGluR1 function, which depends
exclusively on Gq/11 activation. If CHPG functions as a
biased agonist on mGluR1, producing activation of only
the Gi/o pathway, this activity would have been missed. To
assess whether CHPG could activate Gq/11 as effectively as
Glu in cells expressing mGluR5b or mGluR1a, modulation
of the native M-type potassium currents in SCG neurons
was examined. M-currents are non-inactivating, voltage-
dependent potassium currents that are strongly inhibited by
Gq/11 activation [18-20]. In SCG neurons, KV7.2 and KV7.3
(KCNQ2 and KCNQ3) subunits underlie the M-current
[21], and their inhibition is due to depletion of PIP2 levels
by phospholipase C [19,20]. Thus, M-current inhibition by
mGluR1 and 5 functions as a pure assay for Gq/11 activation,
as there is no pertussis toxin sensitive (Gi/o) component to
this modulation [11]. As expected, SCG neurons expressing
mGluR5b were strongly inhibited by both 1 mM CHPG
and 100 μM Glu (Figure 6A). In these cells, the M-current
was inhibited by 78±13%, and 59 ±10% by CHPG and Glu,
respectively (n=3). In 8 mGluR1a-expressing cells exam-
ined, modulation of the M-current by Glu was strong, as
expected, with an average inhibition of 67±8%. However,
the inhibition produced by CHPG in the same cells was
quite variable and on average, much smaller than that pro-
duced by Glu. CHPG inhibition via mGluR1a averaged only
37±15% (Figure 6A, B). Indeed, every cell examined
showed substantial Glu-mediated M-current inhibition, but
only half of these cells exhibited detectable inhibition by
CHPG. This is evident when CHPG inhibition was plotted
vs. Glu inhibition for each cell in Figure 6C. Indeed, the
ratio of CHPG-mediated inhibition to Glu mediated inhib-
ition of the M-current was significantly smaller in mGluR1a
expressing SCG neurons than in mGluR5b expressing cells
(Figure 6A, right), suggesting that CHPG does show some
degree of partial agonism in this system. These data may
Figure 6 Modulation of M-current by CHPG in SCG neurons expressing either mGluR5b or mGluR1a. A, Left, Average (±SEM) calcium
current by 1 mM CHPG (open) and 100 μM Glu (filled), in SCG neurons expressing mGluR5b or mGluR1a, as indicated. Number of cells in each
group is shown in parentheses. Right, Average (±SEM) ratio of CHPG/Glu inhibition of calcium current in the same cells as in Left. Asterisk indicates
p < 0.05, T-test. Note that since ratios are non-linearly distributed around unity, statistical tests were performed on the natural log of the ratio
(CHPG/Glu inhibition) from each individual cell. B, Sample current traces illustrating M-current inhibition in an mGluR1a expressing cell. In this cell,
CHPG had little effect while Glu strongly inhibited the current. M-currents were measured as the tail current deactivating during a hyperpolarizing
step to −60 mV from a holding potential of −30 mV (to inactivate other K+ channels). Voltage protocol is shown below. C, Distribution of percent
inhibition by CHPG plotted against the inhibition by Glu in each cell.
Figure 7 DIfferential mechanism of calcium current modulation
by Glu and CHPG in cells expressing mGluR1a. A, Sample
calcium current traces elicited with the voltage protocol shown
(below) illustrating control and Glu (upper) or CHPG (lower) inhibited
currents in cells expressing either mGluR5b (left) or mGluR1a (right).
Inhibited traces shown in gray. Note that the Gq-mediated
component of inhibition is not reversed by the depolarizing step,
and is therefore similar in both “Pre” and “Post.” Scale bars represent
0.4 nA and 10 msec. B, Summary of the Gq-mediated, voltage
independent component of inhibition (expressed as the Post/Pre
inhibition ratio) for Glu and CHPG (paired measurements in each
cell) from mGluR5 (left) and mGluR1 (right) expressing cells. Number
of cells in each group shown in parentheses.
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here, suggesting that CHPG functions as an agonist with
similar efficacy and potency on mGluR1a as on mGluR5,
and that in the literature, which reports highly selective
effects of CHPG [12]. It should be emphasized however,
that CHPG was not a poor activator of this pathway in
every mGluR1a expressing cell, suggesting that the apparent
biased agonism is complex and may be influenced by other,
as yet undetermined factors.
To further explore the potential biased agonist proper-
ties of CHPG on mGluR1, the calcium current inhibition
via CHPG was examined in more detail. Modulation of
SCG calcium currents by group I mGluRs is complex. Ac-
tivation of both Gi/o and Gq/11 by mGluR1 and 5 leads to
calcium current inhibition, and the two pathways are dis-
tinguishable by their voltage dependence. The pathway
initiated by Gi/o activation is mediated by Gβγ [22], and is
therefore at least partially reversible following a strong de-
polarizing step [23]. By contrast, the Gq/11 mediated inhib-
ition is voltage independent [11]. To evaluate the relative
contributions of these modulatory pathways, a triple pulse
voltage protocol can be used to monitor current amplitude
as the receptors are activated [24] (Figure 7A). This proto-
col consists of two test pulses to +10 mV separated by a
50 msec depolarizing step to +80 mV. Because the de-
polarizing step will selectively reverse much of the Gi/o-
mediated inhibition due to its voltage dependence, the
relative contribution of each G protein pathway to calcium
current inhibition can be gauged by simply dividing the
percent inhibition in the second test pulse (“Post” in
Figure 7A) by that in the first (“Pre”). The higher this in-
hibition ratio, the stronger the relative contribution of the
Gq/11 pathway. However, because the voltage dependent
pathway is not completely reversed by the depolarizing step
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not strictly additive [25], this method cannot be used to
determine the absolute contribution of each pathway.
Nevertheless, to determine whether CHPG was a weaker
activator of Gq/11 then Glu when acting through mGluR1a,
the Post/Pre inhibition ratio was examined during calcium
current inhibition experiments in SCG neurons expressing
either mGluR5b or mGluR1a (Figure 7).
As noted previously [11], the contribution of the volt-
age dependent and voltage independent calcium current
inhibitory pathways via group I mGluRs in SCG neurons
is quite variable. Further, based on the M-current data
(Figure 6), it was expected that any differences in Gq/11
activation by CHPG and Glu would be inconsistent.
Therefore, to insure that any changes would be detect-
able, analysis was restricted to cells in which the Post/
Pre inhibition ratio by 100 μM Glu was 0.35 or higher,
because these cells had a clearly detectable Gq/11 compo-
nent. Figure 7A shows sample current traces illustrating
the voltage dependence of inhibition by 100 μM Glu
(upper) and 1 mM CHPG (lower) in SCG neurons
expressing either mGluR5b (left) or mGluR1a (right).
Figure 7B shows a plot of the Post/Pre inhibition ratio
for Glu and CHPG in each group for every cell in which
the ratio was > 0.35. While there was substantial variability
in the ratios from cell to cell, and in the differences in
ratios between Glu and CHPG, the Post/Pre inhibition
ratios for Glu and CHPG in mGluR5-expressing cells was
statistically indistinguishable. A small but statistically sig-
nificant difference was observed however, in mGluR1a
expressing cells (paired T-test, p≤ 0.05) when comparing
the inhibition by CHPG to that by Glu by providing more
evidence that CHPG is a poorer activator than Glu of the
Gq/11 pathway in some cells. These data lend some support
for the ability of CHPG to act as a biased agonist on
mGluR1, but both the calcium current and M-current in-
hibition data demonstrate that CHPG is capable of activat-
ing Gq/11, even fairly strongly, in some cells.
Discussion
The data presented here indicate that contrary to previous
reports [12], the nominally selective agonist CHPG can ac-
tivate mGluR1 with similar efficacy and potency as
mGluR5. Consistent with the literature however, CHPG
did not produce any detectable activation of mGluR2 or
mGluR4. The effects of CHPG were examined using heter-
ologous expression of each receptor in rat sympathetic
neurons, an adult neuronal cell type with null-mGluR ex-
pression, and assayed using G protein mediated modula-
tion of native ion channel currents as an assay for receptor
signaling. Further, using M-current inhibition as an assay
for receptor function, a pathway that depends only on Gq
signaling, revealed that in some cells, CHPG agonism
of mGluR1 appeared to show some biased agonism.Specifically, while some mGluR1-expressing cells showed
similar M-current inhibition using CHPG or Glu as an
agonist, others were strongly inhibited by Glu, but only
very weakly by CHPG. These data provide some contrast
to those obtained using calcium current inhibition as an
assay, which proceeds through a combination of Gq/11 and
pertussis toxin sensitive Gβγ activation [11]. Examination
of calcium current inhibition by CHPG in mGluR1 expres-
sing cells revealed that the Gq/11-mediated, voltage inde-
pendent inhibitory pathway was not as strongly activated
by CHPG as Glu, supporting the hypothesis that CHPG is
a poorer Gq/11 activator than Glu. However, the difference
was not robust. Thus, while these data indicate that CHPG
can effectively act as an agonist at mGluR1a and its splice
variant mGluR1b, the overall balance of Gi/o/Gq/11 protein
activation may be altered when CHPG rather than Glu is
used as the agonist.
The apparent biased agonism of CHPG when applied
to mGluR1-expressing cells was interesting, but the vari-
ability of the effect is difficult to explain. It is possible
that the variability was related to mGluR1 expression
level, but this conclusion is difficult to reconcile with the
data. Due to the nature of these studies, receptor expres-
sion cannot be directly measured, but an estimate of ex-
pression can be made by assuming that expression level
correlates with the magnitude of inhibition by Glu in
each cell. For example, the M-current inhibition data in
Figure 6 shows that in the 8 mGluR1a expressing cells
examined, M-current inhibition ranged from about 35%
to about 90%. While there may be some relationship be-
tween CHPG responses and Glu responses in these cells,
the relationship is weak. For example, in the 4 cells that
showed virtually no response to CHPG, the range of Glu
responses was quite broad, including two cells with sub-
stantial inhibition by Glu (~ 60 and 80%). Further, exam-
ination of the voltage dependence of calcium current
inhibition (Figure 7) yields similar, ambiguous results
(Figure 8). If the Post/Pre calcium current inhibition
ratio, a measure of the strength of Gq activation by
CHPG, is plotted against the amplitude of total inhib-
ition by Glu, an estimate of expression level, the effects
are widely scattered and poorly correlated (Figure 8).
Thus, the data do not provide strong evidence that the
degree of G protein activation bias by CHPG via mGluR1
is related to receptor expression levels. It should also be
noted that while CHPG was less efficient than Glu at
producing Gq-mediated current inhibition in most of the
mGluR1 expressing cells examined in the calcium
current studies, CHPG still activated this pathway to a
relatively strong degree (Figures 7, 8). Therefore, while
some bias in G protein activation of CHPG via mGluR1
is detectable, it is unlikely that this effect will be mean-
ingful in a physiological or in vivo context. However, the
existence of a group I mGluR agonist with G protein bias
Figure 8 Relative strength of Gq activation by CHPG is not well
correlated with apparent mGluR1 expression level. Relative
strength of the Gq inhibitory pathway, expressed as the Post/Pre
inhibition ratio vs. apparent mGluR1 expression level, expressed as
magnitude of inhibition by 100 μM Glu in each cell. Note that all of
the mGluR1 expressing cells recorded are shown, not just those with
strong Gq components, as in Figure 7.
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with more significant biased properties is possible.
Given the effect of CHPG on mGluR1a, it was not sur-
prising that the drug had similar effects on mGluR1b
since both splice variants are identical in the N-terminal,
ligand binding region. In fact, these proteins differ only
in their extreme cytoplasmic C-termini, which is not
expected to alter receptor pharmacology. Furthermore,
there is no evidence that G protein activation differs in
these splice variants, as both mGluR1a and 1b can pro-
duce qualitatively similar calcium current and M-current
inhibition in SCG neurons [11]. Effects of CHPG on both
variants was tested primarily to confirm the rather sur-
prising result of CHPG agonism on mGluR1, a result
which has not been previously reported despite fairly
widespread use of this drug for over a decade [12,26-29].
Indeed, the mGluR1a data shown in Figure 3B is com-
bined data from SCG neurons expressing mGluR1a from
two separate, but similar, plasmids. One is an untagged
rat mGluR1a, and the other is an N-terminally myc-
tagged mGluR1a, both in pCDNA3.1. The data were
combined because CHPG acted identically on cells
expressing both constructs (not shown). Both constructs
(as well as mGluR1b, in pRK5) were tested for responses
to CHPG, and sequence-verified. Finally, it should be
noted that the results with the mGluR1 constructs were
generated using CHPG from two separate sources
(Tocris and Ascent, see Materials and Methods) with in-
distinguishable results (not shown).Conclusions
The data presented here indicate that contrary to current
dogma, the nominally selective mGluR5 agonist CHPG
can act as an agonist for mGluR1 and 5 with similar effi-
cacy and potency, although under some circumstances
CHPG may be a poorer activator than Glu of Gq/11 via
mGluR1 compared to mGluR5.
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